(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Type 2 Diabetes pipeline constitutes 100+ key companies continuously working towards developing 100+ Type 2 Diabetes treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Type 2 Diabetes Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
“Type 2 Diabetes Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Type 2 Diabetes Market.
Some of the key takeaways from the Type 2 Diabetes Pipeline Report:
- Companies across the globe are diligently working toward developing novel Type 2 Diabetes treatment therapies with a considerable amount of success over the years.
- Type 2 Diabetes companies working in the treatment market are Abarceo Pharma, Carmot Therapeutics, Neurodon, Eccogene, Suzhou Alphamab Co., Ltd, Sciwind Biosciences, Amgen, Regor Pharmaceuticals, Jiangsu Hengrui Medicine Co, Celon Pharma, Oramed Pharmaceuticals, Eli Lilly and Company, Novo Nordisk, and others, are developing therapies for the Type 2 Diabetes treatment
- Emerging Type 2 Diabetes therapies in the different phases of clinical trials are- type 2 diabetes mellitus therapeutics, CT996, NRDN-101, ECC5004, KN056, XW014, AMG 133, RGT001-075, HR17031, CPL207280, ORMD-0801, LY-3209590, Insulin icodec, and others are expected to have a significant impact on the Type 2 Diabetes market in the coming years.
- In August 2023, The first medication from a novel drug class known as glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonists, or simply GLP-1 and GIP receptor agonists, has been approved by the Food and Drug Administration (FDA) and is sold under the brand name Mounjaro.
- In May 2022, According to Lilly, after the U.S. Food and Drug Administration gave Mounjaro a type 2 diabetes approval, the organisation gave it a fast-track designation five months later to hasten the examination of outcomes from two Phase III clinical trials looking into it as a weight-loss medication.
- In May 2021, Once weekly insulin icodec and once daily insulin glargine 100 Units/mL, both in combination with bolus insulin with or without non-insulin anti-diabetic medicines, were compared for their effects and safety in a 26-week trial started by Novo Nordisk in patients with Type 2 Diabetes on a Basal-Bolus Regimen.
Type 2 Diabetes Overview
Diabetes is a long-term metabolic disorder marked by high or low blood glucose (also known as blood sugar) levels. Over time, diabetes causes considerable harm to the heart, blood vessels, eyes, kidneys, and nerves. Diabetes is caused by either inadequate cell responses to insulin action or insufficient insulin synthesis (made by the pancreas and decreased blood glucose).
Get a Free Sample PDF Report to know more about Type 2 Diabetes Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/type-2-diabetes-pipeline-insight
Emerging Type 2 Diabetes Drugs Under Different Phases of Clinical Development Include:
- Research programme: type 2 diabetes mellitus therapeutics: Abarceo Pharma
- CT996: Carmot Therapeutics
- NRDN-101: Neurodon
- ECC5004: Eccogene
- KN056: Suzhou Alphamab Co., Ltd
- XW014: Sciwind Biosciences
- AMG 133: Amgen
- RGT001-075: Regor Pharmaceuticals
- HR17031: Jiangsu Hengrui Medicine Co
- CPL207280: Celon Pharma
- ORMD-0801: Oramed Pharmaceuticals
- LY-3209590: Eli Lilly and Company
- Insulin icodec: Novo Nordisk
Type 2 Diabetes Route of Administration
Type 2 Diabetes pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
- Intra-articular
- Intraocular
- Intrathecal
- Intravenous
- Ophthalmic
- Oral
- Parenteral
- Subcutaneous
- Topical
- Transdermal
- Molecule Type
Type 2 Diabetes Molecule Type
Type 2 Diabetes Products have been categorized under various Molecule types, such as
- Oligonucleotide
- Peptide
- Small molecule
- Product Type
Type 2 Diabetes Pipeline Therapeutics Assessment
- Type 2 Diabetes Assessment by Product Type
- Type 2 Diabetes By Stage and Product Type
- Type 2 Diabetes Assessment by Route of Administration
- Type 2 Diabetes By Stage and Route of Administration
- Type 2 Diabetes Assessment by Molecule Type
- Type 2 Diabetes by Stage and Molecule Type
DelveInsight’s Type 2 Diabetes Report covers around 100+ products under different phases of clinical development like
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I)
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Further Type 2 Diabetes product details are provided in the report. Download the Type 2 Diabetes pipeline report to learn more about the emerging Type 2 Diabetes therapies
Some of the key companies in the Type 2 Diabetes Therapeutics Market include:
Key companies developing therapies for Type 2 Diabetes are – Eli Lilly and Company, Regor Pharmaceuticals Inc., AstraZeneca, Eccogene, Pfizer, Sciwind Biosciences USA Co., Ltd., MediciNova, Sparrow Pharmaceuticals, HighTide Biopharma Pty Ltd, Novo Nordisk A/S, Biomea Fusion Inc., Altimmune, Inc., Novartis, Amgen, Neuraly, Inc., Carmot Therapeutics, Inc., Inventiva Pharma, Inversago Pharma Inc, Applied Therapeutics, Inc., and others.
Type 2 Diabetes Pipeline Analysis:
The Type 2 Diabetes pipeline report provides insights into
- The report provides detailed insights about companies that are developing therapies for the treatment of Type 2 Diabetes with aggregate therapies developed by each company for the same.
- It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Type 2 Diabetes Treatment.
- Type 2 Diabetes key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Type 2 Diabetes Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Type 2 Diabetes market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Type 2 Diabetes drugs and therapies
Type 2 Diabetes Pipeline Market Drivers
- Increasing Prevalence, government bodies are collaborating with major market players for the launch of new products, increase in the demand for insulin over the world are some of the important factors that are fueling the Type 2 Diabetes Market.
Type 2 Diabetes Pipeline Market Barriers
- However, side-effects associated with the treatment of Type 2 Diabetes, a lack of knowledge about a healthy diet, medication initiation and other factors are creating obstacles in the Type 2 Diabetes Market growth.
Scope of Type 2 Diabetes Pipeline Drug Insight
- Coverage: Global
- Key Type 2 Diabetes Companies: Abarceo Pharma, Carmot Therapeutics, Neurodon, Eccogene, Suzhou Alphamab Co., Ltd, Sciwind Biosciences, Amgen, Regor Pharmaceuticals, Jiangsu Hengrui Medicine Co, Celon Pharma, Oramed Pharmaceuticals, Eli Lilly and Company, Novo Nordisk, and others
- Key Type 2 Diabetes Therapies: type 2 diabetes mellitus therapeutics, CT996, NRDN-101, ECC5004, KN056, XW014, AMG 133, RGT001-075, HR17031, CPL207280, ORMD-0801, LY-3209590, Insulin icodec, and others
- Type 2 Diabetes Therapeutic Assessment: Type 2 Diabetes current marketed and Type 2 Diabetes emerging therapies
- Type 2 Diabetes Market Dynamics: Type 2 Diabetes market drivers and Type 2 Diabetes market barriers
Request for Sample PDF Report for Type 2 Diabetes Pipeline Assessment and clinical trials
Table of Contents
1. Type 2 Diabetes Report Introduction
2. Type 2 Diabetes Executive Summary
3. Type 2 Diabetes Overview
4. Type 2 Diabetes- Analytical Perspective In-depth Commercial Assessment
5. Type 2 Diabetes Pipeline Therapeutics
6. Type 2 Diabetes Late Stage Products (Phase II/III)
7. Type 2 Diabetes Mid Stage Products (Phase II)
8. Type 2 Diabetes Early Stage Products (Phase I)
9. Type 2 Diabetes Preclinical Stage Products
10. Type 2 Diabetes Therapeutics Assessment
11. Type 2 Diabetes Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Type 2 Diabetes Key Companies
14. Type 2 Diabetes Key Products
15. Type 2 Diabetes Unmet Needs
16 . Type 2 Diabetes Market Drivers and Barriers
17. Type 2 Diabetes Future Perspectives and Conclusion
18. Type 2 Diabetes Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/competitive-intelligence-services